- Friday 1st of October 2021
Which laboratory values may Malegra 25 mg long-term use?
Malegra 25 mg contains sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor used to treat erectile dysfunction. It is generally considered safe for long-term use when prescribed, but certain laboratory values may be monitored over time—especially in patients with underlying health conditions. Laboratory Values That May Be Affected or Monitored Liver Function Tests (LFTs) ALT (Alanine aminotransferase) AST (Aspartate aminotransferase) Rarely, Malegra 25 mg may cause mild elevations in liver enzymes. Monitoring is more important in patients with liver disease. Kidney Function Tests Serum creatinine Blood urea nitrogen (BUN) While sildenafil does not typically damage kidneys, impaired renal function can affect drug clearance. Blood Pressure Not a lab test, but important clinically. Sildenafil can lower blood pressure, especially when combined with nitrates or antihypertensive drugs. Cardiac Markers (if indicated) In patients with heart disease, physicians may monitor overall cardiovascular status rather than specific routine lab abnormalities caused by the drug. Complete Blood Count (CBC) No consistent long-term changes are expected, but monitoring may occur in patients with complex medical conditions. Important Note Long-term use of sildenafil does not typically cause significant laboratory abnormalities in healthy individuals. Most monitoring is precautionary and tailored to a patient’s medical history (e.g., liver, kidney, or cardiovascular disease).
Latest News
- Friday 1st of October 2021
“BIZ 2021” Entrepreneurial Day competition
- Friday 1st of October 2021
Workshop on modern assessment and the Use of Zoom Software in Learner-Centered Classroom (Academic staff)
- Friday 19th of March 2021
“Let’s Plant Trees for a Better Environment 2021”
- Friday 19th of March 2021
Biz 2020 – UWU Entrepreneurs’ Day
- Friday 19th of March 2021
Faculty of Management signs MoU with the Sri Lanka Institute of Marketing
- Friday 19th of March 2021
0 Replies:
Leave a Reply